ASXL2 and pancreatic adenocarcinoma: In addition, Kaplan-Meier survival analyses showed that patients with low ASXL2 expression survival longer than those with high ASXL2 expression, which highlights the prognostic value of ASXL2 in PAAD (Figures 5C, D).